Andrew Goldberg's most recent trade in Tarsus Pharmaceuticals Inc was a trade of 4,540 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 4,540 | 4,540 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 3,350 | 0 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 3,350 | 16,700 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 2,954 | 2,954 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 7,000 | 0 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.89 per share. | 07 Mar 2025 | 7,000 | 13,350 | - | 12.9 | 90,230 | Common Stock |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 3,350 | 6,350 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 3,350 | 0 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 3,350 | 3,350 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Purchase of securities on an exchange or from another person at price $ 18.96 per share. | 15 Dec 2023 | 1,000 | 3,000 | - | 19.0 | 18,960 | Common Stock |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 3,350 | 3,350 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 2,000 | 2,000 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 2,000 | 0 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Andrew Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) |